Skip to content

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

Tracking and Predicting Neurodegeneration Spreading Across the Brain Connectome

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07567664
Enrollment
645
Registered
2026-05-05
Start date
2017-06-01
Completion date
2027-03-01
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative Disease, Behavioral Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia(PPA), Progressive Supranuclear Palsy(PSP), Amyotrophic Lateral Sclerosis (ALS), Cortical Basal Syndrome (CBS)

Brief summary

Neurodegenerative diseases, including frontotemporal lobar degeneration (FTLD) spectrum syndromes, are characterized by the accumulation of insoluble protein aggregates in the central nervous system. A common feature of these diseases is that pathological changes accumulate over time following a stereotyped spatial pattern, which contributes to the onset and progression of clinical symptoms. Until recently, the causes of such progression were still unknown. Recent pathological and neuroimaging studies have, however, suggested that insoluble and pathological protein aggregates are able to alter the conformation of neighboring proteins and spread through cell-to-cell transmission. According to this theory, called the 'brain connectome,' the brain network is established as a set of nodes, which correspond to different anatomical regions. These brain networks are highly connected to each other and their internal organization is fundamental for an efficient integration of information coming from different regions and to guarantee adequate levels of motor/cognitive performance. Thanks to magnetic resonance studies and research in the field of brain networks, it is possible to understand the pathophysiology of neurodegenerative diseases and reveal the connectivity profiles associated with different clinical outcomes. The main objective of this project is to explore the mechanisms of neurodegeneration associated with the different FTLD spectrum syndromes, and in particular the hypothesis that the neurodegenerative process is driven by the structural architecture of the brain 'connectome'. The ultimate goal is to apply mathematical models to structural and functional connectivity data to predict the evolution of the neurodegenerative process in sporadic and genetic forms of Frontotemporal Lobar Degeneration Disease. This study aims to investigate the spatiotemporal progression of neurodegeneration in frontotemporal lobar degeneration (FTLD) using advanced neuroimaging and connectomics. 360 patients with sporadic FTLD (including bvFTD, semantic and nonfluent PPA, PSPs, CBS, and ALS) and 65 patients with genetic FTLD (MAPT, GRN, and C9orf72 mutati will be enrolled. The study also plans to enroll 120 subjects who are members of families carrying FLTD-associated mutations (including 60 mutation carriers). Finally, 100 healthy controls will also be enrolled, including 50 young healthy controls and 50 healthy controls comparable with patients by sex and age. Participants will undergo clinical, neuropsychological, and behavioral assessments, blood and Cerebrospinal fluid (CSF) collection, and multimodal 3Tesla Magnetic Resonance Imaging MRI at baseline and every 6 months for up to 2 years. Primary objectives include mapping longitudinal changes in structural and functional brain networks, developing predictive models of network degeneration and clinical decline, and characterizing protein-specific patterns of network degeneration. Secondary aims include identifying early network biomarkers in presymptomatic carriers and correlating network changes with biological markers.

Interventions

DIAGNOSTIC_TEST3 Tesla MRI without contrast medium

3 Tesla MRI examination without contrast medium in which resting functional MRI sequences, diffusion-weighted sequence, structural MRI sequences will be obtained

During the screening/basal visit, a blood sample will be taken to assess the genetic profile of patients, consanguineous family members, and healthy elderly controls. Objective is to evaluate the major genes that have been shown to play a role in the pathogenesis of FTLD The genes GRN, MAPT, C9orf72, TARDBP, SOD1, FUS, OPTN, VCP will be analyzed.

DIAGNOSTIC_TESTCerebrospinal fluid sampling (CSF)

During the baseline visit, patients will undergo lumbar puncture for the collection of CSF for quantification of biological biomarkers

A neurological evaluation will be conducted in order to be able to exclude from the study all participants with a history of psychiatric illness, head injury, alcohol or psychotropic substance use

DIAGNOSTIC_TESTNeuropsychological evaluation

A neuropsychological assessment will be conducted in order to be able to exclude from the study all participants with a history of psychiatric illness, alcohol or psychotropic substance use

Sponsors

IRCCS San Raffaele
Lead SponsorOTHER
IRCCS Besta Neurological Institute, Milan, Italy
CollaboratorUNKNOWN
Azienda Ospedaliera San Gerardo di Monza
CollaboratorOTHER
Istituto Auxologico Italiano
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Intervention, multicentric and multiparametric study

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

Adult participants, under 85 years of age, diagnosed with bvFTD, semantic variant PPA, non-fluent variant PPA, PSP, CBS, and early-stage ALS, according to the criteria of Rascovsky (2011), Gorno-Tempini (2011), Litvan (1996), Armstrong (2013), and Brooks (2000), respectively; Participants with genetic forms of FTLD associated with mutations in the c9orf72, GRN, MAPT genes, and asymptomatic family members related to FTLD patients carrying such mutations Healthy participants (age between 20 and 30 years old); Healthy participants matched to patients for age and sex

Exclusion criteria

* Participants with a history of other neurological and/or psychiatric disorders, head trauma, alcohol or psychoactive substance use, or a family history of other neurodegenerative diseases.

Design outcomes

Primary

MeasureTime frameDescription
Longitudinal change in the structural connectome via Neurite Orientation Dispersion and Density Imaging (NODDI)6 months, 12 months, 18 months, 24 monthsEvaluating structural white matter integrity over time through graph-theoretical analysis based on NODDI-derived metrics
Longitudinal change in the structural connectome via Diffusion Tensor Imaging (DTI)6 months, 12 months, 18 months, 24 monthsEvaluating structural white matter integrity over time through graph-theoretical analysis
Longitudinal change in brain functional connectome via functional MRI6 months, 12 months, 18 months, 24 monthsEvaluating functional brain changes in functional brain networks using graph-theoretical analysis of fMRI-derived connectivity
Prediction of pathological spreading through the structural connectome6 months, 12 months, 18 months, 24 monthsTo predict spatial and temporal spreading of neurodegeneration through the structural connectome using network diffusion model

Countries

Italy

Contacts

STUDY_DIRECTORProf. Massimo Filippi

IRCCS San Raffaele

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026